RNAC
Cartesian Therapeutics, Inc.8.29
-0.68-7.58%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
215.57MP/E (TTM)
-Basic EPS (TTM)
-1.33Dividend Yield
0%Recent Filings
8-K
Phase 3 MG enrollment on track
Cartesian Therapeutics issued its January 2026 corporate update, confirming Phase 3 AURORA enrollment on track for Descartes-08 in myasthenia gravis. FDA accepted IND for myositis Phase 2 trial starting 1H26; pediatric HELIOS trial initiated. Cash of $145.1M funds operations into mid-2027. Pipeline advances swiftly.
8-K
Appoints CAR T expert Bot
Cartesian Therapeutics appointed Adrian Bot, M.D., Ph.D., a CAR T veteran from Kite and Capstan, as Class II director effective December 16, 2025. He joins the Science and Technology Committee with $40,000 annual retainer, options for 17,200 shares at $8.29, and RSUs for 5,800 shares. His cell and gene therapy expertise bolsters R&D oversight. Board also updated its ethics code, tightening BYOD data rules.
8-K
Strong SLE data, myositis pivot
Cartesian Therapeutics disclosed initial Phase 2 data for Descartes-08 in SLE: 100% LLDAS response in 3 patients at Month 3, 2/3 DORIS remission, well-tolerated outpatient without chemo. Pausing SLE and Descartes-15 to prioritize MG Phase 3 and myositis Phase 2 starting 1H26. Cash lasts through mid-2027. Pivotal myositis path awaits interim data.
10-Q
Q3 FY2025 results
Cartesian Therapeutics posted Q3 results ending September 30, 2025, with financial statements showing no revenue disclosed and ongoing operating losses typical for clinical-stage biotech, while balance sheets reflect cash position and stockholders' deficit as of quarter-end. Cash flow statements for nine months ended September 30 cover operating, investing, and financing activities, but specific y/y or q/q deltas for revenue, margins, EPS, or FCF not highlighted in the filing. No non-GAAP metrics defined or reconciled in the 10-Q. Debt, M&A, or regulatory updates absent. Liquidity relies on quarter-end cash amid burn. Clinical trial delays pose key risk.
8-K
Q3 loss widens on trial ramp
Cartesian Therapeutics reported Q3 2025 net loss of $35.9M, up from $24.2M last year, driven by higher R&D on the Phase 3 AURORA trial for Descartes-08 in myasthenia gravis—enrollment on track. Cash stands at $145.1M, funding operations into mid-2027. Preliminary Phase 2 SLE data due year-end. Expenses climbed, yet runway holds firm.
IPO
Employees
Sector
Industry
ACET
Adicet Bio, Inc.
0.47-0.03
CABA
Cabaletta Bio, Inc.
2.39+0.00
CRBU
Caribou Biosciences, Inc.
1.69-0.02
DNTH
Dianthus Therapeutics, Inc.
41.40-0.52
DSGN
Design Therapeutics, Inc.
9.62+0.50
FATE
Fate Therapeutics, Inc.
1.09-0.03
KYTX
Kyverna Therapeutics, Inc.
10.24-0.58
LEGN
Legend Biotech Corporation
21.65-0.36
MRKR
Marker Therapeutics, Inc.
1.27-0.12
NKTX
Nkarta, Inc.
1.82-0.02